Pharmac Funds New Medicine And Removes Renewal Criteria For ADHD And Narcolepsy Treatments
“We’ve decided to fund lisdexamfetamine, a new stimulant medicine that will provide an additional treatment option for people with ADHD, and we’re also simplifying the renewal process,” says Pharmac’s Chief Medical Officer, Dr David Hughes.